# Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent

Study · id `cardio:ct-nct01681095` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01681095](<https://clinicaltrials.gov/study/NCT01681095>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01681095

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Valve and congenital heart disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT01681095. Randomized; no masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2017-03-01.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT01681095, source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01681095, source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01681095, source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)
- Completion: 2016-04 (actual) (ClinicalTrials.gov record NCT01681095, source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)
- Results first posted: 2017-03-01 (ClinicalTrials.gov record NCT01681095, source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01681095, source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01681095-2019-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
- Condition: Coronary Artery Disease
- Condition: Myocardial Ischemia
- Condition: Coronary Disease
- Condition: Heart Diseases
- Condition: Valvular Heart Disease
- Intervention (Drug): Custodiol HTK
- Intervention (Drug): Cold Blood Cardioplegia
- Lead sponsor: Marc Sakwa, MD
- Lead sponsor class: OTHER
- Collaborator: Essential Pharmaceuticals, LLC
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 039921d7631cd23ce9377b9206010e9f66bec0780e9c8fd02cd66f475c2bc443
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
